Adoptive T-cell therapy for the treatment of solid tumours

Keith L Knutson, Bond Almand, David A. Mankoff, Kathy Schiffman, Mary L. Disis

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Solid tumours can be eradicated by infusion of large amounts of tumour-specific T-cells in animal models. The successes seen in preclinical models, however, have not been adequately translated to human disease due, in part, to the inability to expand tumour antigen-specific T-cells ex vivo. Polyclonality and retention of antigen-specificity are two important properties of infused T-cells that are necessary for successful eradication of tumours. Investigators are beginning to evaluate the impact of attempting to reconstitute full T-cell immunity representing both major T-cell subsets, cytolytic T-cells and T-helper (Th) cells. One of the more important and often overlooked steps of successful adoptive T-cell therapy is the ex vivo expansion conditions, which can dramatically alter the phenotype of the T-cell. A number of cytokines and other soluble activation factors that have been characterised over the last decade are now available to supplement in vitro antigen presentation and IL-2. Newer molecular techniques have been developed and are aimed at genetically altering the characteristics of T-cells including their antigen-specificity and growth in vivo. In addition, advanced imaging techniques, such as positron emission tomography (PET), are being implemented in order to better define the in vivo function of ex vivo expanded tumour-specific T-cells.

Original languageEnglish (US)
Pages (from-to)55-66
Number of pages12
JournalExpert Opinion on Biological Therapy
Volume2
Issue number1
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

T-cells
Cell- and Tissue-Based Therapy
Tumors
T-Lymphocytes
Neoplasms
Therapeutics
Antigens
Antigen Presentation
Positron emission tomography
T-Lymphocyte Subsets
Neoplasm Antigens
Helper-Inducer T-Lymphocytes
Positron-Emission Tomography
Interleukin-2
Immunity
Animal Models
Research Personnel
Animals
Cytokines
Chemical activation

Keywords

  • Cancer
  • Cytokine
  • Cytotoxic T-cells (CTL)
  • Dendritic cells
  • ex vivo expansion
  • Polyclonal
  • T-cell receptor
  • T-helper cell
  • Vaccine

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Genetics
  • Immunology
  • Pharmacology

Cite this

Adoptive T-cell therapy for the treatment of solid tumours. / Knutson, Keith L; Almand, Bond; Mankoff, David A.; Schiffman, Kathy; Disis, Mary L.

In: Expert Opinion on Biological Therapy, Vol. 2, No. 1, 2002, p. 55-66.

Research output: Contribution to journalArticle

Knutson, Keith L ; Almand, Bond ; Mankoff, David A. ; Schiffman, Kathy ; Disis, Mary L. / Adoptive T-cell therapy for the treatment of solid tumours. In: Expert Opinion on Biological Therapy. 2002 ; Vol. 2, No. 1. pp. 55-66.
@article{4e2e0ad241534ae19c3fd6998079dde7,
title = "Adoptive T-cell therapy for the treatment of solid tumours",
abstract = "Solid tumours can be eradicated by infusion of large amounts of tumour-specific T-cells in animal models. The successes seen in preclinical models, however, have not been adequately translated to human disease due, in part, to the inability to expand tumour antigen-specific T-cells ex vivo. Polyclonality and retention of antigen-specificity are two important properties of infused T-cells that are necessary for successful eradication of tumours. Investigators are beginning to evaluate the impact of attempting to reconstitute full T-cell immunity representing both major T-cell subsets, cytolytic T-cells and T-helper (Th) cells. One of the more important and often overlooked steps of successful adoptive T-cell therapy is the ex vivo expansion conditions, which can dramatically alter the phenotype of the T-cell. A number of cytokines and other soluble activation factors that have been characterised over the last decade are now available to supplement in vitro antigen presentation and IL-2. Newer molecular techniques have been developed and are aimed at genetically altering the characteristics of T-cells including their antigen-specificity and growth in vivo. In addition, advanced imaging techniques, such as positron emission tomography (PET), are being implemented in order to better define the in vivo function of ex vivo expanded tumour-specific T-cells.",
keywords = "Cancer, Cytokine, Cytotoxic T-cells (CTL), Dendritic cells, ex vivo expansion, Polyclonal, T-cell receptor, T-helper cell, Vaccine",
author = "Knutson, {Keith L} and Bond Almand and Mankoff, {David A.} and Kathy Schiffman and Disis, {Mary L.}",
year = "2002",
doi = "10.1517/14712598.2.1.55",
language = "English (US)",
volume = "2",
pages = "55--66",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Adoptive T-cell therapy for the treatment of solid tumours

AU - Knutson, Keith L

AU - Almand, Bond

AU - Mankoff, David A.

AU - Schiffman, Kathy

AU - Disis, Mary L.

PY - 2002

Y1 - 2002

N2 - Solid tumours can be eradicated by infusion of large amounts of tumour-specific T-cells in animal models. The successes seen in preclinical models, however, have not been adequately translated to human disease due, in part, to the inability to expand tumour antigen-specific T-cells ex vivo. Polyclonality and retention of antigen-specificity are two important properties of infused T-cells that are necessary for successful eradication of tumours. Investigators are beginning to evaluate the impact of attempting to reconstitute full T-cell immunity representing both major T-cell subsets, cytolytic T-cells and T-helper (Th) cells. One of the more important and often overlooked steps of successful adoptive T-cell therapy is the ex vivo expansion conditions, which can dramatically alter the phenotype of the T-cell. A number of cytokines and other soluble activation factors that have been characterised over the last decade are now available to supplement in vitro antigen presentation and IL-2. Newer molecular techniques have been developed and are aimed at genetically altering the characteristics of T-cells including their antigen-specificity and growth in vivo. In addition, advanced imaging techniques, such as positron emission tomography (PET), are being implemented in order to better define the in vivo function of ex vivo expanded tumour-specific T-cells.

AB - Solid tumours can be eradicated by infusion of large amounts of tumour-specific T-cells in animal models. The successes seen in preclinical models, however, have not been adequately translated to human disease due, in part, to the inability to expand tumour antigen-specific T-cells ex vivo. Polyclonality and retention of antigen-specificity are two important properties of infused T-cells that are necessary for successful eradication of tumours. Investigators are beginning to evaluate the impact of attempting to reconstitute full T-cell immunity representing both major T-cell subsets, cytolytic T-cells and T-helper (Th) cells. One of the more important and often overlooked steps of successful adoptive T-cell therapy is the ex vivo expansion conditions, which can dramatically alter the phenotype of the T-cell. A number of cytokines and other soluble activation factors that have been characterised over the last decade are now available to supplement in vitro antigen presentation and IL-2. Newer molecular techniques have been developed and are aimed at genetically altering the characteristics of T-cells including their antigen-specificity and growth in vivo. In addition, advanced imaging techniques, such as positron emission tomography (PET), are being implemented in order to better define the in vivo function of ex vivo expanded tumour-specific T-cells.

KW - Cancer

KW - Cytokine

KW - Cytotoxic T-cells (CTL)

KW - Dendritic cells

KW - ex vivo expansion

KW - Polyclonal

KW - T-cell receptor

KW - T-helper cell

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0035989684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035989684&partnerID=8YFLogxK

U2 - 10.1517/14712598.2.1.55

DO - 10.1517/14712598.2.1.55

M3 - Article

C2 - 11772340

AN - SCOPUS:0035989684

VL - 2

SP - 55

EP - 66

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 1

ER -